SCHEMBL3594929

SCHEMBL3594929

C[C@](Cc1ccccc1)(NC(=O)O)C(O)CN

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.48
CYP1A2 P05177 2/20 0.48
RECQL P46063 2/20 0.48
MAPK1 P28482 1/20 0.47
CYP2C9 P11712 2/20 0.43
CYP2C19 P33261 2/20 0.43
ALDH1A1 P00352 2/20 0.43
CYP2D6 P10635 2/20 0.41
TRPA1 O75762 1/20 0.41
TSHR P16473 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HIF1A Q16665 1/20 0.41
SLC6A2 P23975 1/20 0.41
TAAR1 Q96RJ0 1/20 0.41
MMP8 P22894 4/20 0.40
OPRM1 P35372 1/20 0.39
OPRD1 P41143 1/20 0.39
OPRK1 P41145 1/20 0.39
LMNA P02545 1/20 0.39
NPC1 O15118 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4743524 1.00 CYP3A4 (0.48) CYP3A4CYP1A2RECQLMAPK1CYP2C9
SCHEMBL6466848 0.85 CA12 (0.44) CYP3A4CYP1A2RECQLMAPK1ALDH1A1
SCHEMBL12417601 0.75 TRPA1 (0.59) CYP3A4CYP1A2RECQLMAPK1CYP2C9
SCHEMBL4027524 0.74 CYP3A4 (0.53) CYP3A4CYP1A2RECQLMAPK1CYP2C9
SCHEMBL25270848 0.74 NPC1 (0.46) CYP1A2RECQLCYP2C9CYP2C19MMP8
SCHEMBL5948337 0.73 CYP3A4 (0.67) CYP3A4CYP1A2RECQLMAPK1CYP2C9
SCHEMBL4583207 0.72 CYP3A4 (0.50) CYP3A4CYP1A2RECQLMAPK1CYP2C9
SCHEMBL4352382 0.72 LTA4H (0.50) ALDH1A1SMN1; SMN2MAPTRAB9A
SCHEMBL18342202 0.71 CYP3A4 (0.47) CYP3A4CYP1A2RECQLMAPK1CYP2C9
SCHEMBL11700362 0.71 TRPA1 (0.46) CYP3A4CYP1A2RECQLMAPK1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1740559-B1 1,3,5-SUBSTITUTED PHENYL DERIVATIVE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME (US) 2014-10-15 EP disclosed
US-7847100-B2 1,3,5-substituted phenyl derivative compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's disease Merck, Sharp & Dohme, Inc. (US) 2010-12-07 US disclosed
US-20070244119-A1 1,3,5-Substituted Phenyl Derivative Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease MERCK SHARP & DOHME LLC 2007-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244119-A1 1,3,5-Substituted Phenyl Derivative Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease BACE1, BACE2, PSEN1 CYP3A4 1045/4885CYP1A2 1158/4885RECQL 3009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.